British Axial Spondyloarthritis Inception Cohort

Patients newly diagnosed with axial spondyloarthritis are being enrolled into a UK-wide study that tracks their symptoms, treatment, and ability to work over time. The problem this addresses is that axial spondyloarthritis—a chronic inflammatory condition affecting the spine and joints—often goes undiagnosed for years, during which pain, stiffness, and fatigue can force people out of work and reduce their quality of life. Current evidence on how diagnostic delay affects long-term outcomes is limited, and most data come from outside the UK. This study fills that gap by collecting real-world information directly from patients in British rheumatology clinics who have not yet received biologic therapies. If the research succeeds, it will provide clear evidence on how quickly diagnosis needs to happen to preserve people’s ability to hold down jobs and maintain daily function. That could change clinical guidelines, prompting faster referral pathways from GPs to rheumatologists. It may also help the NHS allocate resources more effectively—for example, by identifying which patients benefit most from early biologic treatment. The findings could ultimately reduce the long-term disability and economic burden that axial spondyloarthritis currently places on individuals and the healthcare system.